On Invalid Date, Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q4 2023 earnings per share (EPS) of $0.01, up 0% year over year. Total Rigel Pharmaceuticals earnings for the quarter were $737.00 thousand. In the same quarter last year, Rigel Pharmaceuticals's earnings per share (EPS) was $0.01.
As of Q2 2024, Rigel Pharmaceuticals's earnings has grown year over year. Rigel Pharmaceuticals's earnings in the past year totalled -$25.09 million.
What is RIGL's earnings date?
Rigel Pharmaceuticals's earnings date is Invalid Date. Add RIGL to your watchlist to be reminded of RIGL's next earnings announcement.
What was RIGL's revenue last quarter?
On Invalid Date, Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q4 2023 revenue of $35.79 million up 30.2% year over year. In the same quarter last year, Rigel Pharmaceuticals's revenue was $51.28 million.
What was RIGL's revenue growth in the past year?
As of Q2 2024, Rigel Pharmaceuticals's revenue has grown -2.79% year over year. This is 147.42 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Rigel Pharmaceuticals's revenue in the past year totalled $116.88 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.